• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

WHO grants nonproprietary name to ovarian cancer cell therapy

by Marisa Wexler, MS | Nov 19, 2025 | Myeloma News

A committee of the World Health Organization (WHO) has approved an international nonproprietary name (INN) for Anixa Biosciences’ experimental cell therapy for ovarian cancer. The therapy, which is already in clinical testing, will now carry the INN liraltagene...

Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases

by MM360 Staff | Nov 19, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Carvykti label updated to include survival benefit data in myeloma

by Marisa Wexler, MS | Nov 18, 2025 | Myeloma News

Regulators in the U.S. and Europe have approved updates to the prescribing information for Carvykti (ciltacabtagene autoleucel), a cell therapy used to treat hard-to-manage myeloma. The updates include survival data from the ongoing CARTITUDE-4 (NCT04181827) Phase 3...

Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

by MM360 Staff | Nov 18, 2025 | Publications

Front Oncol. 2025 Oct 30;15:1619115. doi: 10.3389/fonc.2025.1619115. eCollection 2025. ABSTRACT BACKGROUND: Triplet regimens, such as bortezomib-lenalidomide-dexamethasone (VRd) and bortezomib-melphalan-prednisone (VMP), were standard treatments for newly diagnosed...

Inflammatory markers from routine blood tests predict survival in multiple myeloma: a Systematic Review and meta-analysis

by MM360 Staff | Nov 18, 2025 | Publications

Front Immunol. 2025 Oct 30;16:1669878. doi: 10.3389/fimmu.2025.1669878. eCollection 2025. ABSTRACT BACKGROUND: Multiple myeloma (MM) is an incurable hematologic malignancy marked by abnormal plasma cell proliferation. Inflammatory indices derived from routine blood...
« Older Entries
Next Entries »

Recent Content

  • Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • Daily pill to stop pancreatic cancer spread granted FDA orphan drug status
  • CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT